Randomised controlled trial to determine efficacy and safety of prescribed water intake to prevent the progression of autosomal dominant polycystic kidney disease (PREVENT-ADPKD)

随机对照试验，以确定处方水摄入量预防常染色体显性多囊肾病 (PREVENT-ADPKD) 进展的有效性和安全性

• 批准号: nhmrc : GNT1138533
• 负责人: A/Pr Anna Rangan
• 金额: $ 74.68万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/randomised-controlled-trial-prevent-adpkd/1348155
• 关键词: Randomised; controlled; trial; determine; efficacy

Increasing the daily intake of water is well known to reduce the risk of developing kidney stones but there is growing evidence that it may also benefit other kidney diseases, particularly autosomal dominant polycystic kidney disease (ADPKD). This study will determine if adequate hydration can slow the progression of ADPKD, and could provide a relatively simple and cheap treatment for preventing the onset of kidney failure due to this disease.

众所周知，增加每日水的摄入量可以降低患肾结石的风险，但越来越多的证据表明，它也可能有益于其他肾脏疾病，特别是常染色体显性多囊肾病（ADPKD）。这项研究将确定适当的水合作用是否可以减缓ADPKD的进展，并可以提供一种相对简单和廉价的治疗方法来预防这种疾病引起的肾衰竭。